RedHill Biopharma reported $1.29M in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 67.33M 65.44M Dec/2025
Cronos Group USD 58.39M 22.05M Dec/2025
RedHill Biopharma USD 1.29M 722K Jun/2024